Close Menu

NEW YORK – Cancer Genetics reported on Monday that its fourth quarter revenues grew about 12 percent year over year, which the firm noted was  partially the result of the adoption of the new ASC 606 revenue recognition standard and the variability in project start and end times at the individual contract level in the firm's discovery services business unit.

For the three months ended Dec. 31, 2019, the firm reported total revenues from continuing operations of $1.9 million, up from $1.7 million in the fourth quarter of 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.